These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 7851473)

  • 1. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1994 Oct; 264(2):117-23. PubMed ID: 7851473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1993 Jul; 238(2-3):235-40. PubMed ID: 8104807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tremor activity of talipexole produced by selective dopamine D2 receptor stimulation in cynomolgus monkeys with unilateral lesions in the ventromedial tegmentum.
    Kohno Y; Fukuzaki K; Kitahara K; Koja T
    Eur J Pharmacol; 1997 Jan; 319(2-3):197-205. PubMed ID: 9042591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
    Domino EF; Ni L; Zhang H; Kohno Y; Sasa M
    Eur J Pharmacol; 1997 May; 325(2-3):137-44. PubMed ID: 9163560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
    Pearce RK; Jackson M; Britton DR; Shiosaki K; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1999 Feb; 142(1):51-60. PubMed ID: 10102782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
    Zubair M; Jackson MJ; Tayarani-Binazir K; Stockwell KA; Smith LA; Rose S; Olanow W; Jenner P
    Exp Neurol; 2007 Dec; 208(2):177-84. PubMed ID: 17935716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.
    Jackson MJ; Andree TH; Hansard M; Hoffman DC; Hurtt MR; Kehne JH; Pitler TA; Smith LA; Stack G; Jenner P
    J Neural Transm (Vienna); 2010 Jan; 117(1):55-67. PubMed ID: 19809864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
    Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ropinirole on motor behavior in MPTP-treated common marmosets.
    Fukuzaki K; Kamenosono T; Kitazumi K; Nagata R
    Pharmacol Biochem Behav; 2000 Sep; 67(1):121-9. PubMed ID: 11113491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
    Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Jenner P
    Mov Disord; 2001 Jul; 16(4):631-41. PubMed ID: 11481686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Ann Neurol; 1998 Apr; 43(4):507-13. PubMed ID: 9546333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
    Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P
    Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.